Ravulizumab
Contents
Description
Ravulizumab is a long-acting C5 complement inhibitor used across multiple rare complement-mediated disorders, including paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. It is a major specialty biologic because of its extended dosing interval and broad orphan footprint across hematology, nephrology, and neurology. The product is widely tracked in global access discussions due to its high-cost biologic profile and infusion-center requirements.
Indications & Therapeutic Use
paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, generalized myasthenia gravis, neuromyelitis optica spectrum disorder
Linked Diseases:
Global Availability (5 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Buy / Source Ravulizumab — GNH India
15 matching products available through GNH India. Select a product to view details and request a quote on the GNH India website.
Browse all Ravulizumab products on GNH IndiaProducts and ordering are fulfilled by GNH India. You will be redirected to www.gnhindia.com.
Available Through
This drug is available for procurement through the following fulfilment partner.
| Generic Name | ravulizumab |
| Brands | 1 brand available |
| Active Ingredient | ravulizumab |
| Drug Class | paroxysmal nocturnal hemoglobinuria |
| Manufacturer | Alexion Pharmaceuticals |
| Dosage Forms | Concentrate for solution for infusion |
| Medical Code | L04AJ |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Required |
| Reg. Status | FDA Approved |
| Clinical Trial | NCT04119050 |
| Countries | 5 countries |